Liposomal doxorubicin doubly functionalized with CCK8 and R8 peptide sequences for selective intracellular drug delivery

Journal of Peptide Science

Volumn 21, Issue 5, 2015, Pages 415-425

  Ringhieri, Paola ^a   Diaferia, Carlo ^a   Galdiero, Stefania ^a   Palumbo, Rosanna ^b   Morelli, Giancarlo ^a   Accardo, Antonella ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

cell penetrating peptides; click chemistry; drug delivery systems; homing peptides; liposomes

Indexed keywords

CELL PENETRATING PEPTIDE; CYTOKERATIN 8; DITHIOTHREITOL; DOXORUBICIN; LIPOSOME; R8 CELL PENETRATING PEPTIDE; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE; OCTA-ARGININE PEPTIDE; OLIGOPEPTIDE; PEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; DISULFIDE BOND; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; TARGET CELL; ANALOGS AND DERIVATIVES; CHEMISTRY; HUMAN; SYNTHESIS; TUMOR CELL LINE;

CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; OLIGOPEPTIDES; PEPTIDES; POLYETHYLENE GLYCOLS;

EID: 84928784909     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2759     Document Type: Article

References (44)

1. Martinez JO, Evangelopoulos M, Karun V, Shegog E, Wang JA, Liu X, Ferrari M, Boada C, Tasciotti E,. The effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulation. Biomaterials 2014; 35 (37): 9824-9832.
2. Mei L, Fu L, Shi K, Zang Q, Liu Y, Tang J, Gao H, Zang Z, He Q,. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG. Int. J. Pharm. 2014; 468 (1-2): 26-38.
3. Accardo A, Salsano G, Morisco A, Aurilio M, Parisi A, Maione F, Cicala C, Tesauro D, Aloj L, De Rosa G, Morelli G,. Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent. Int. J. Nanomed. 2012; 7: 2007-2017.
4. Morisco A, Accardo A, Tesauro D, Palumbo R, Benedetti E, Morelli G,. Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells. Biopolymers (Pept. Sci.) 2011; 96 (1): 88-96.
5. Ringhieri P, Iannitti R, Nardon C, Palumbo R, Fregona D, Morelli G, Accardo A,. Target selective micelles for bombesin receptors incorporating Au(III)-dithiocarbamato complexes. Int. J. Pharm. 2014; 473 (1-2): 194-202.
6. Tarallo R, Accardo A, Falanga A, Guarnieri D, Vitiello G, Netti P, D'Errico G, Morelli G, Galdiero S,. Clickable functionalization of liposomes with the gH625 peptide from Herpes simplex virus type i for intracellular drug delivery. Chem. Eur. J. 2011; 17 (45): 12659-12668.
7. Wang Y, Zhou J, Qiu L, Wang X, Chen L, Liu T, Di W,. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells. Biomaterials 2014; 35 (14): 4297-4309.
8. Carberry TP, Tarallo R, Falanga A, Finamore E, Galdiero M, Weck M, Galdiero S,. Dendrimer functionalization with a membrane-interacting domain of herpes simplex virus type 1: towards intracellular delivery. Chem. Eur. J. 2012; 18: 13678-13685.
9. Lee Y, Graeser R, Kratz F, Geckeler KE,. Paclitaxel-loaded polymer nanoparticles for the reversal of multidrug resistance in breast cancer cells. Adv. Funct. Mater. 2011; 21: 4211-4218.
10. Falanga A, Vitiello MT, Cantisani M, Tarallo R, Guarnieri D, Mignogna E, Netti P, Pedone C, Galdiero M, Galdiero S,. A peptide derived from herpes simplex virus type 1 glycoprotein H: membrane translocation and applications to the delivery of quantum dots. Nanomedicine 2011; 7: 925-934.
11. Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, van Oosterom AT, Clemons MJ, Kamby C, Hermans C, Whittaker J, Donato di Paola E, Verweij J, Nielsen S,. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 2001; 37: 870-877.
12. Duggan ST, Keating GM,. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS related Kaposi's sarcoma. Drugs 2011; 71: 2531-2558.
13. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak S, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C,. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004; 15: 440-449.
14. Yang ZZ, Li JQ, Wang ZZ, Dong DW, Qi XR,. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials 2014; 35 (19): 5226-5239.
15. Yu MK, Park J, Jon S,. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostic 2012; 2 (1): 3-44.
16. Accardo A, Tesauro D, Morelli G,. Peptide-based targeting strategies for simultaneous imaging and therapy with nanovectors. Polym. J. 2013; 45 (5): 481-493.
17. Copolovici DM, Langel K, Eriste E, Langel U,. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano 2014; 8 (3): 1972-1994.
18. Guarnieri D, Falanga A, Muscetti O, Tarallo R, Fusco S, Galdiero M, Galdiero S, Netti PA,. Shuttle-mediated nanoparticle delivery to the blood-brain barrier. Small 2013; 9 (6): 853-862.
19. Yang Y, Yang Y, Xie X, Cai X, Zhang H, Gong W, Wang Z, Mei X,. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy. Biomaterials 2014; 35 (14): 4368-4381.
20. Silvente-Poirot S, Dufresne M, Vaysse N, Fourmy D,. The peripheral cholecystokinin receptors. Eur. J. Biochem. 1993; 215: 513-529.
21. Wank SA,. Cholecystokinin receptors. Am. J. Physiol. 1995; 269: G628.
22. Laverman P, Behe M, Oyen WJG, Willems PHGM, Corstens FHM, Behr TM, Boerman OC,. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scinitigraphic imaging of CCK receptors. Bioconjugate Chem. 2004; 15: 561-568.
23. Reubi JC, Schaer JC, Waser B,. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997; 57: 1377-1386.
24. Tornesello AL, Aurilio M, Accardo A, Tarallo L, Barbieri A, Arra C, Tesauro D, Morelli G, Aloj L,. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison. J. Pept. Sci. 2011; 17 (5): 405-412.
25. Accardo A, Tesauro D, Mangiapia G, Pedone C, Morelli G,. Nanostructures by self-assembling peptide amphiphile as potential selective drug carriers. Biopolymers (Pept. Sci.) 2007; 88: 115-121.
26. Accardo A, Tesauro D, Aloj L, Tarallo L, Arra C, Mangiapia G, Vaccaro M, Pedone C, Paduano L, Morelli G,. Peptide containing aggregates as selective nanocarriers for therapeutics. ChemMedChem 2008; 3 (4): 594-602.
27. Nakase I, Akita H, Kogure K, Graslund A, Langel U, Harashima H, Futaki S,. Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Acc. Chem. Res. 2012; 45 (7): 1132-1139.
28. Galdiero S, Vitiello M, Falanga A, Cantisani M, Incoronato N, Galdiero M,. Intracellular delivery: exploiting viral membranotropic peptides. Curr. Drug Metab. 2012; 13: 93-104.
29. Biswas S, Deshpande PP, Perche F, Dodwadkar NS, Sane SD, Torchilin VP,. Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett. 2013; 335 (1): 191-200.
30. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y,. Arginine-rich peptides: an abundant source of membrane permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 2001; 276: 5836-5840.
31. Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, Torchilin VP,. "SMART" drug delivery systems: double-targeted ph-responsive pharmaceutical nanocarriers. Bioconjugate Chem. 2006; 17: 943-949.
32. Schmitt L, Dietrich C, Tampe R,. Synthesis and characterization of chelator-lipids for reversible immobilization of engineered proteins at self-assembled lipid interfaces. J. Am. Chem. Soc. 1994; 116: 8485-8491.
33. Accardo A, Ringhieri P, Tesauro D, Morelli G,. Liposomes derivatized with tetrabranched neurotensin peptides via click chemistry reactions. New J. Chem. 2013; 37: 3528-3534.
34. Tesauro D, Accardo A, Gianolio E, Paduano L, Teixeira J, Schillén K, Aime S, Morelli G,. Peptide derivatized lamellar aggregates as target-specific MRI contrast agents. Chem. Bio. Chem. 2007; 8 (8): 950-955.
35. Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Süss R,. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. BBA Biomembrane. 2006; 1758: 1633-1640.
36. Aloj L, Panico M, Caracò C, Del Vecchio S, Arra C, Affuso A, Accardo A, Mansi R, Tesauro D, De Luca S, Pedone C, Visentin R, Mazzi U, Morelli G, Salvatore M,. In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK8 derivatives for CCK-B receptor imaging. Cancer Biother. Radiopharm. 2004; 19: 91-96.
37. Feldborg LN, Jølck RI, Andresen TL,. Quantitative evaluation of bioorthogonal chemistries for surface functionalization of nanoparticles. Bioconjugate Chem. 2012; 23: 2444-2450.
38. Jullian M, Hernandez A, Maurras A, Puget K, Amblard M, Martinez J, Subra G,. N-Terminus FITC labeling of peptides on solid support: the truth behind the spacer. Tetrahedron Lett. 2009; 50: 260-263.
39. Li X, Zhao Y,. Protection/deprotection of surface activity and its applications in the controlled release of liposomal contents. Langmuir 2012; 28 (9): 4152-4159.
40. Zhang S, Zhao Y,. Controlled release from cleavable polymerized liposomes upon redox and pH stimulation. Bioconjugate Chem. 2011; 22 (4): 523-528.
41. Giustarini D, Dalle-Donne I, Colombo R, Milzani A, Rossi R,. Is ascorbate able to reduce disulfide bridges? A cautionary note. Nitric Oxide 2008; 19: 252-258.
42. Landino LM, Koumas MT, Mason CE, Alston JA,. Ascorbic acid reduction of microtubule protein disulfides and its relevance to protein S-nitrosylation assays. Biochem. Biophys. Res. Commun. 2006; 340: 347-352.
43. Markoutsa E, Papadia K, Giannou AD, Spella M, Cagnotto A, Salmona M, Stathopoulos GT, Antimisiaris SG,. Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies. Pharm. Res. 2014; 31: 1275-1289.
44. Takara K, Hatakejama H, Kibria G, Ohga N, Hida K, Harashima H,. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. J. Control. Rel. 2012; 162: 225-232.